Gilteritinib
Another week, another FDA-approval for AML. We discuss the latest in #oncopharm approvals: the FLT3-inhibitor gilteritinib. For more background reading, try here: https://doi.org/10.1177%2F1078155218802620
Dec 05, 2018•17 min
OncoPharm
OncoPharm is a podcast dedicated to all things oncology pharmacy. Most episodes cover updates and recent publications concerning the use of medications in caring for patients with cancer. Periodically, episodes drop devoted to Landmark Clinical Trials in oncology and Fundamentals of Oncology Pharmacy.
Last refreshed: ⓘ
Follow this podcast in the Metacast mobile app to refresh it and see new episodes.
Podcasts are better in Metacast mobile app
Don't just listen to podcasts. Learn from them with transcripts, summaries, and chapters for every episode. Skim, search, and bookmark insights. Learn more
Episodes
Elderly AML & Larotrectinib
The often encountered, seldom studied Elderly AML demographic is discussed in light of recent FDA approvals for glasdegib (new drug) and venetoclax (new indication). Then, (17:30) we discuss the 2nd drug "tissue agnostic" FDA approval by delving into NTRK-fusion-gene tumors and larotrectinib.
Nov 27, 2018•27 min
Rise (& Fall) Of ESAs
Describing the rationale for and rise in widespread ESA use for cancer patients going back 30 years....and why their use has been drastically curtailed in the last decade.
Nov 21, 2018•22 min
Cyclophosphamide
Discussing one of the main workhorse #oncopharm agents: cyclophosphamide. Topics include is bioactivation, myriad of uses, toxicity (hemorrhagic cystits) prevention and management.
Nov 15, 2018•19 min
Lorlatinib
Reviewing the latest TKI approved for ALK rearranged metastatic NSCLC. And hey, how 'bout that crazy rifampin hepatotoxicity interaction?
Nov 06, 2018•24 min
October '18 Updates
Running through recent notable updates on pembrolizumab, olaparib, atezolizumab, palbociclib and 5F9's introduction.
Nov 01, 2018•21 min
Flu Vaccine Use with Immunotherapy
Discussing the scant evidence regarding influenza vaccination in cancer patients receiving immunotherapy. Warning! - unpublished abstracts are discussed by a guy with laryngitis.
Oct 25, 2018•11 min
Talazoparib
Another new #oncopharm agent was approved. We talk about talazoparib and how it compares to olaparib for germline BRCA-mutated breast cancer.
Oct 18, 2018•14 min
P1: Tamoxifen for Breast Cancer Risk Reduction
The Landmarks in Oncology Pharmacy series returns with the P1 study. We review this landmark paper paving the way for breast cancer risk reduction (or chemoprevention) and discuss the mark or lack thereof (frown emoji) it has made in clinical practice.
Oct 11, 2018•16 min
Dacomitinib, cemiplimab & #oncopharm updates
Dacomitinib & cemiplimab's respective FDA-approvals are discussed followed by a lightning-round review of 4 immunotherapy studies from the last week. We end with dosing updates for 2 multiple myeloma drugs.
Oct 04, 2018•28 min
Duvelisib
The latest #oncopharm approval for duvelisib is discussed as well as the similarities and differences to other PI3K inhibitors previously approved.
Sep 26, 2018•18 min
The Pseudomonas Exotoxin Drug
Discussing the new pseudomonas exotoxin drug (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia (3rd line). Lots of supportive care measures required, surprisingly, for the pseudomonas exotoxin drug.
Sep 20, 2018•12 min
*Bonus Pod* World Marrow Donor Day '18
Celebrating World Marrow Donor Day by recapping the HSCT donation experience of your favorite podcast host.
Sep 15, 2018•16 min
5-Fluorouracil
5-FU: both its mechanisms, all its toxicities, most of its uses, and some of its history are discussed.
Sep 14, 2018•18 min
Ask OncoPharm (Part 1) & RELEVANCE
The debut of our mailbag (Ask OncoPharm) to give some tips to new oncology pharmacists. Then (13:10) we review the RELEVANCE study of rituximab/lenalidomide in follicular lymphoma.
Sep 06, 2018•22 min
Influenza Vaccination during Chemo
It's flu shot season, so we're taking a pseudo-systematic review of influenza vaccination in patient receiving chemotherapy. Questions addressed include: How effective is influenza vaccination for cancer patients? What's the optimal timing of vaccination during chemo?
Aug 30, 2018•29 min
Small Cell Lung Cancer: Established & Recent Advances
Small cell lung cancer is reviewed, including the milestone advances (chemo + RT, omitting surgery, cis/etoposide) of the past leading up to the latest advance (15:20) - FDA-approval of nivolumab in the 3rd-line setting.
Aug 23, 2018•24 min
Mogamulizumab & August updates
Mogamulizumab-kpkc (MOAs, administration, toxicity) and its FDA-approval is discussed followed by (9:00) updates lenvatinib (a good update) and azithromycin (a bad update) in cancer patients.
Aug 16, 2018•14 min
Rituximab
We explore the origins of rituximab's dose, geek out on the NNT in DLBC, and discuss other "need to know" tidbits.
Aug 09, 2018•19 min
Iobenguane I-131 & Lusutrombopag
Catching up the recent FDA-approvals for iobenguane I-131 (and its myriad of precautions) and lusutrombopag.
Aug 02, 2018•13 min
Ivosidenib
After running through recent FDA updates (including ribociclib's approval in PRE-menopausal breast cancer patients), the newly approved ivosidenib is discussed.
Jul 26, 2018•13 min
A Brief History of Pemetrexed
Ten years ago a preplanned subgroup analysis changed the NSCLC treatment algorithms. We go back to the beginning with pemetrexed and the studies leading up to the oft-cited Scagliotti that ushered in histology-specific treatment in NSCLC.
Jul 20, 2018•15 min
Paclitaxel
We discuss paclitaxel, from its discovery to its uses to toxicity and their management as part of our Landmarks in #OncoPharm series. And if you really, really love this drug - you'll learn where to may homage at a historical marker in....
Jul 11, 2018•17 min
Happy Fourth!
Our shortest Pod yet! Chemotherapy explosions and photosensitizing antineoplastics are discussed.
Jul 04, 2018•7 min
Encorafenib & Binimetinib
The newly FDA-approved BRAF & MEK inhibitors are discussed, along with their possible clinical relevance and some notable differences compared to previously available BRAF & MEK inhibitors.
Jun 28, 2018•18 min
The Immunotherapy Two Step
Immunotherapy takes two steps forward (new FDA approvals)....and two steps backwards. These updates in #oncopharm are discussed before ending (11:45) with discussions of venetoclax's expanded approval in CLL, the bevacizumab approval almost 7 years in the making, and late-breaking information on preventing cisplatin ototoxicity.
Jun 21, 2018•18 min
Ondansetron Origins
The Landmarks in Oncology Pharmacy series returns with a review of 2 ondansetron studies from 1990, published simultaneously in NEJM.
Jun 13, 2018•16 min
Less is More & More
Recapping (some) of the top stories from ASCO18 starting with breast cancer (TAILOR-Rx, PERSEPHONE, SANDPIPER, S0927); then NSCLC (11:35) with Keynote-42 & LOXO-292; then mylemoa (16:50) with a CAR-T update and a new dosing of carfilzomib; before ending (20:30) with CARMENA and PRODIGY-24's new mFOLFIRINOX data for adjuvant pancreatic cancer. Whew!
Jun 07, 2018•24 min
ASCO18 & Under the Radar Abstracts
Previewing this week's ASCO annual meeting and the Plenary Sessions (briefly) and selected abstracts highlighting oncology pharmacy practice.
May 31, 2018•16 min
Avatrombopag
Avatrombopag's FDA-approval prompts discussion of both the indication and drug itself. Finally, the publication of the SELECT-D study allows us to dig deeper into the data of a DOAC vs. LMWH in cancer-associated VTE.
May 25, 2018•17 min
For the best experience, listen in Metacast app for iOS or Android